Loading stock data…
DBV Technologies S.A (DBVT)
$16.14+0.13 (+0.81%)
Market OpenUpdated 3:08 PM EDT
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
DBV Technologies S.A. in the Healthcare sector is trading at $16.14 with a market capitalization of $1.0B. Wall Street consensus targets $39.96 (6 analysts), implying a +147.6% move over the next 12 months. The stock is currently 38% below its 52-week high of $26.18, remaining 9.4% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +147.6% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$47.90M↓ | -$45.05M↓ | -$34.28M↑ | -$41.11M↓ | -$26.60M |
| Net Income | -$47.60M↓ | -$44.83M↓ | -$33.16M↑ | -$41.88M↓ | -$27.10M |
Peer Comparison
JNJUNHPFE
Fundamentals
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.03B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-80.51%
Volume
Today's trading volume
285,586
Recent News
European Equities Traded in the US as American Depositary Receipts Track Higher in Monday Trading
European equities traded in the US as American depositary receipts were trending higher late Monday
European Equities Traded in US as ADRs Rise in Thursday Trading
European equities traded in the US as American depositary receipts rose late Thursday morning with t
European Equities Traded in the US as American Depositary Receipts Fall Sharply in Tuesday Trading
European equities traded in the US as American depositary receipts were tracking sharply lower late
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading
European equities traded in the US as American depositary receipts started the week higher late Mond
DBV Technologies (ENXTPA:DBV) Advances Peanut Patch With New Phase 3 Data And Infant Trial
DBV Technologies is presenting new positive Phase 3 data for its VIASKIN Peanut Patch, including results in children with additional atopic conditions. The company has also started a Phase 2 trial in infants as young as six months, the youngest group yet targeted for peanut allergy immunotherapy. Both updates are being highlighted at a major scientific congress, expanding visibility for DBV Technologies and its allergy treatment platform. DBV Technologies (ENXTPA:DBV) is putting a spotlight...